Generalized resistance to thyroid hormone (GRTH) is a syndrome of variable reduction of tissue responsiveness to thyroid hormone. 28 different point mutations in the human thyroid hormone receptor beta (TRY8) gene have been associated with GRTH. These mutations are clustered in two regions of the T3 binding domain of the TRY6 (codons 310-347 and 417453). We now report point mutations in the TRIf gene of six additional families with GRTH and show that three mutations occurred each in three families with GRTH, and that three other mutations were each present in two families. In 11 of these 15 families, lack of a common ancestor could be confirmed by genetic analysis. 28 of the 38 point mutations so far identified, including all those occurring in more than one family, are located in cytosine-guanine-rich areas of the TRY gene. Differences in clinical and laboratory findings in unrelated families harboring the same TRfY mutation suggest that genetic variability of other factors modulate the expression of thyroid hormone action. (J. Clin. Invest. 1993.91:2408-2415
Introduction
Generalized resistance to thyroid hormone (GRTH)' is an inherited condition ofreduced target tissue responsiveness to thyroid hormone characterized by a nonsuppressed thyrotropin (TSH) in spite of high concentrations ofthyroid hormone (1) . It has long been suspected that the condition is due to abnormalities at the level of the thyroid hormone receptor (TR) (2, 3) . The detection of two genes (TRa and TRI3 located on different chromosomes) that encode nuclear proteins with identi- 1 . Abbreviations used in thispaper: FT4, free thyroxine; GRTH, generalized resistance to thyroid hormone; TR, thyroid hormone receptor; TSH, thyrotropin; TT4, total thyroxine; TT3, total triiodothyronine. cal thyroid hormone binding properties (4) led to the demonstration of linkage of the TR#3 gene with GRTH (5) . Subsequently, a single basepair substitution in the hormone binding domain of the TR#3 was described in affected members of a family with GRTH (6). 28 point mutations have been since described in families with GRTH (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . With the exception of one mutation (16) , all cluster in two regions in the triiodothyronine (T3) binding domain of the TR,3 (codons 310-347 and 417-453). Codons are numbered according to the corrected coding sequence of the TRf3 gene, which adds 5 amino acids to the amino terminus (23) .
Each family with GRTH up until the present report was believed to have a unique mutation. Based on this latter finding, it was anticipated that differences in functional impairment ofthe mutant TRs would explain the variable manifestations ofGRTH among families. Such relation has been demonstrated in vitro but not in vivo. Mammalian cells transfected with mutant TRs having lower binding affinity for T3 required higher concentrations of the hormone to produce transactivation of a cotransfected thyroid hormone responsive reporter gene (24, 25) . Surprisingly, this correlation was not found in vivo in terms of the severity of clinical manifestations. More specifically, subjects expressing the mutant TRI3 with fivefoldreduced T3-binding affinity had more severe impairment of mental function and growth than individuals from another family expressing a mutant TR with more than 100-fold-reduced T3-binding affinity (6, 7, 26) . This discrepancy was present despite similar levels of endogenous thyroid hormone and the presence of unaltered expression of both mutant and normal TRIP genes in the heterozygous affected subjects (27) .
Sequence analysis of the TRl3 gene in more families with GRTH has led to the recognition of identical mutations in apparently unrelated families. We now report identical nucleotide substitution in the TR3 gene occurring in affected members of different families with GRTH. Three of these mutations were each found in three families and three others, each in two families. In 11 of the 15 families, lack of a common ancestor was confirmed by genetic analysis. The mutations in six ofthe families have not been previously reported. All identical mutations occurred in cytosine(C)-guanine(G)-rich regions of the TRj3 gene. Differences in clinical and laboratory findings in unrelated families harboring the same TRIP mutation suggest that additional factors modulate the expression of the thyroid hormone resistance. Subjects. 61 affected subjects belonging to 15 families are included in the study. Data from thyroid function tests and, when applicable, references to the first description of the families appear in Table I . All subjects had inappropriately normal TSH with elevated thyroid hormones, indicating reduced pituitary sensitivity to thyroid hormone. They had no symptoms or signs of thyrotoxicosis. The majority of subjects had goiters, and those tested failed to respond normally to the administration of supraphysiologic doses of T3 or T4.
DNA sequencing. DNA was isolated from peripheral blood leukocytes and/or from cultured skin fibroblasts (33) . It was used for subsequent analyses and for TRB gene sequencing of at least one affected member of each family. Exons 6, 7, and 8, comprising 75% of the T3-binding region ofthe TRB, were separately amplified using the PCR (35) . For details on the structure of the TR# gene, see Takada et al. (34) . The conditions ofthe reactions and the sequences ofthe oligonucleotides were those published by Usala et al. (36) . The amplified DNA fragments were cloned into the M1 3 bacteriophage vector and sequenced by the dideoxynucleotide chain termination method (37) using Sequenase.
Confirmation ofmutations. Several techniques were used to determine the presence or absence of each mutation in family members. Allele-specific amplification (6) was used to confirm the mutations in families F52 and F89. The identification of families (F followed by a number) is according to the tabulation of all published families with GRTH (38) . DNA from each individual was subjected to two PCRs, one with a pair of oligonucleotide primers, 5'-GGAGAT-CATGTCCCTTCGCG-3' ("normal primer") and 5'-AAAGCT-CTTTGGATCCCCACTAACGAG-3' (primer a) and the other with a pair of primers, one of which contained the mutant nucleotide (5'-GGAGATCATGTCCCTTCGCA-3', mutant nucleotide underlined).
Allele-specific amplification was not successful in confirming all mutations due to nonspecific amplification. Furthermore, not every mutation resulted in the creation or loss of a restriction endonuclease site. An alternative and novel approach to the confirmation of mutations was the synthesis of degenerate oligonucleotide primers complementary to sequences near the mutated nucleotide that produced a novel specific restriction site only if the DNA template contained the expected nucleotide substitution. Following amplification of the subjects' DNA by PCR, the DNA fragments were submitted to electrophoresis in acrylamide gel or in 3% NuSieve/ 1% agarose gel, before and after digestion with the specific enzyme. Partial cleavage of a DNA fragment indicated that the mutant nucleotide was present in one ofthe two alleles. A 20mer oligonucleotide primer was used for confirming the mutation in family F88 resulting in a new DraIII site (degenerated nucleotides are underlined): 5'ATGTCCCTTCGCGCACTGT-3' and in families F29 and F106 resulting in a new NcoI site: 5'ATGGGGAAATGGCAGTGCCA-3'. The antisense oligonucleotide primer used in these reactions was the same (5'-AAAGCTCG-GATCCCCACTAACGAG-3'). In family F95, however, the mutation itself resulted in a new restriction site (ApaLI), and the primers used were the same as for amplifying the exon for sequencing.
Confirmation ofgenetic unrelatedness by dinucleotide repeat polymorphism. The presence ofdinucleotide (CA) repeat polymorphism in the TRB intron flanked by exons 2 and 3 (39) was used to determine whether members from different families harboring identical TRfl mutations had a common ancestor. A 197-209 bp fragment containing the region of variable lengths of CA repeats was amplified by PCR using oligonucleotide primers labeled at their 5' end with 35P by the kinase reaction. The resulting products were resolved on a polyacrylamide sequencing gel as described by Sakurai et al. (39) .
Tests ofthyroidfunction. Sera were available from individuals belonging to families F29, F45, F52, F88, F89, F95, and F106. Total thyroxine (TT4) and triiodothyronine (TT3) were measured by radioimmunoassays (Diagnostic Products Corp., Los Angeles, CA) and TSH by ELISA-2 (Nichols, San Juan Capastrano, CA). Free thyroxine 
Results
Six distinct mutations were found in 15 families, each present in at least two families (Table II) . Seven of these families were studied in our laboratory, six of which have not been previously reported (see Table I ). In the latter families, the presence of a nucleotide substitution in the TRf3 gene of all subjects affected by GRTH but not in normal relatives was confirmed. Allele-specific amplification was used to demonstrate the substitution of the normal G-1234 by an A (Ml) in affected subjects offamilies F52 and F89. As shown in Fig. 1 , this mutation was absent in the nonaffected natural parents of the 9-yr-old twin boys of family F52, indicating a de novo mutation. An identical mutation was found by sequencing and confirmed by the allele-specific amplification in a woman with GRTH (F89) who was 31 yr old at the time of diagnosis. This patient was adopted and no other family members were available for testing.
The creation ofa new ApaLI restriction site by the substitution ofG-1244 by A (M3) was used to confirm the mutation in all affected members of family F95. An alternative approach, that of the loss of the recognition site for HhaI, was used by Cugini et al. ( 12) to identify the identical mutation in another family (F67) . Confirmation that two other mutations were present only in subjects affected by GRTH necessitated the use of a degenerate oligonucleotide primer (see Methods), which together with the mutated nucleotide created a specific restriction site. This is illustrated in Fig. 2 for the detection of the substituted C-1243 for T (M2) in family F88, creating a new recognition site for DraIII. The same strategy was used to confirm the presence of specific nucleotide substitutions in the Evidence for the de novo occurrence of mutation M1 in families F52 and F100 is based on the observation that the parents offamilies F52 (Fig. 1) and F100 (8) were not affected. Since affected members of these families were 11 yr old or younger and thus not in the reproductive age, the identical mutation found in the adopted subject of family F89 has occurred independently of the mutations in families F52 and F100. The criteria used to determine the genetic relatedness in all families with identical mutations in the T3-binding domain of the TR#3 gene are shown in Table III .
Because clinical observations suggested that differences in the manifestations of GRTH existed not only among families with different mutations but also between families with the same mutation, we attempted to establish the presence of heterogeneity by more objective means. Since mean serum TSH levels were normal and not significantly different among the 10 families for whom sufficient data were available, we examined the corresponding mean serum T4 and T3 concentrations re- quired to maintain comparable TSH levels. One pair of families (F54 and F88) with mutation M2 had significantly different mean TT4 values (P < 0.02), and another family pair (F67 and F95) with mutation M3 showed significant difference (P < 0.02) in their mean TT3 concentration (Table I) . Free T4 level rather than TT4, TT3, or free T3 correlates best with the feedback regulation ofTSH and is a measure of pituitary sensitivity to thyroid hormone (41, 42) . We therefore compared the mean Ff4 values among the families. Values were expressed as percent above the upper limit of normal in order to reduce the error in comparing data obtained by different laboratories. As shown in Fig. 4 , significant differences were observed in free T4 levels between families with mutation M3 and those with M4 and M5. More surprisingly, a highly significant difference (P < 0.02) in mean free T4 values was also found between families F54 and F88, both harboring the same M2 mutation. each reporting seven and nine families, respectively (8, 9) , also failed to show identical mutations in different families. We currently report six different mutations each present in 2 or 3 of 15 unrelated families. Obviously the need to confirm that the families with identical mutations have no common ancestor is not trivial. A physician may have sent patient material to more than one laboratory or the common ancestor may be distant and unknown to the families in question. Indeed, the mutation in the TR#3 gene in one individual was reported by Parilla et al.
(8) as case 1 of family F-W, and by us as subject VII-1 (9), independently. This subject with GRTH was first reported by Kaplowitz et al. (43) and then studied by us (29, 44, 45) . After subsequent adoption, he moved to another state and came to the attention of Parilla et al. (8) .
The criteria used to determine the genetic relation between families harboring identical mutations are listed in Table III coding sequence. Furthermore, of the six mutations found to occur independently in 15 unrelated families, five (Ml, M2, M3, M4, and M5) were in regions of CG repeats and one (M6) in an area of C repeats. This is significant because such sequences are thought to be mutational hot spots in humans since they are frequent sites of polymorphisms (46) . Regions with the dinucleotide CG in the Factor IX gene had a 77-fold increase in the mutation rate compared with the rates of other regions (47) . In a review of single base-pair substitutions that cause human genetic diseases (excluding hemophilia), 32% of point mutations were CG to TG or CG to CA transitions (48) . This represents a 12-fold higher frequency than that predicted to occur at random. The mechanism of this phenomenon appears to be methylation of cytosine 5' to guanine and the subsequent spontaneous deamination of 5-methylcytosine to thymine, which is not excised by the enzyme DNA-uracil glycosidase (49) . GRTH, therefore, seems similar to other genetic diseases in humans in the frequency of this type of mutation, which was present in 14 of the 38 reported mutations (37%) with 27 of 38 (71%) occurring in CG-rich regions. Of the 34 point mutations recently described in the human androgen receptor (50-54), 15 were T and A transitions occurring in CGdinucleotides (53%) but only 6 (21%) occurred in CG-rich areas as defined above.
It is of interest that mutations have not been described be- contains CG rich sequences. This region of the TRf3 gene encodes the heptad repeats forming a "leucine zipper" structure that is involved in receptor dimerization (55) (56) (57) (26, 27) is supported by the current data. In contrast to former studies, we had the opportunity to compare the free T4 levels required to maintain the same TSH value in four pairs of families, each with identical mutations of the TRf gene. In one pair of families, F54 and F88, the mean free T4 concentration was significantly different at P < 0.02 (Fig. 4) . Although differences in other clinical characteristics, such as hyperactivity and bone maturation, were also observed between families with identical point mutations, they were difficult to quantify because ofdifferences in subjects' ages. This is not to say that the degree ofimpairment ofT3-binding does not contribute to the severity of the hormone resistance. It should be noted that the two families with mutation M3 had significantly lower free T4 values than families with mutation M5, as well as three-fold higher affinity for T3 of their M3-mutant TR3 (Table I, Fig. 5 ).
The possibility that the observed biochemical and clinical differences among families harboring identical mutations in the T3-binding domain of the TRj3 may be due to a second mutation in the TRf3 deserves serious consideration. Such mutations have not been detected in four families with GRTH in whom the entire coding region of the TRIO gene has been sequenced (6, 9, 15, 16) and in two families in whom sequencing comprised the T3-binding, DNA-binding, and hinge regions ( 12, 13) . In addition, screening for mutations upstream of the T3-binding domain, including 75% ofthe DNA binding region, in six ofthe families described herein (F25, F45, F52, F88, F89 , and F95) also failed to show an additional mutation (9) . Furthermore, it can be speculated that functionally important mutations in the DNA-binding domain are less likely to have a significant biological effect in the heterozygous state since, as shown by site-directed mutagenesis (59), such mutations have no dominant negative effect. Thus, the most likely explanation for the apparent TR3 mutation independent differences in the degree of thyroid hormone resistance among families is the genetic variability of other factors that are involved in the expression of thyroid hormone action. Current evidence indicates that another thyroid hormone receptor (TRa, located on chromosome 17), a number of transactivation protein cofactors (RXRa and RXR,3), and less well-defined auxiliary TR proteins interact in the expression of thyroid hormone action (56, 60, 61 ) . The interaction results in the formation of stable complexes that bind to specific DNA sequences (thyroid hormone response elements) present in genes regulated by thyroid hormone. Undoubtedly, each of the involved factors and elements is subject to genetic polymorphism, which modulates its structure, interaction, and function. The genetically determined form and expression of a particular coregulator may diminish or augment the hormonal resistance imparted by a particular mutation in the TRfl gene and thus contribute to the modulation of the phenotype of GRTH. 
